Pure Global

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium - Trial NCT05718934

Access comprehensive clinical trial information for NCT05718934 through Pure Global AI's free database. This Phase 4 trial is sponsored by Ciusss de L'Est de l'Île de Montréal and is currently Recruiting. The study focuses on Neuromuscular Blockade. Target enrollment is 144 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05718934
Phase 4
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05718934
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium
A Randomized Clinical Study to Compare Low Dose of Sugammadex to Standard Dose of Neostigmine and Glycopyrrolate for the Reversal of Rocuronium Induced Moderate Neuromuscular Block

Study Focus

Neuromuscular Blockade

Neostigmine and glycopyrrolate

Interventional

drug

Sponsor & Location

Ciusss de L'Est de l'Île de Montréal

Montreal, Canada

Timeline & Enrollment

Phase 4

Nov 08, 2022

Nov 01, 2023

144 participants

Primary Outcome

Time for recovery from moderate NMB

Summary

The aim of this study is to compare the use of a low dose sugammadex and neostigmine combined
 to glycopyrrolate to reverse a rocuronium induced moderate neuromuscular blockade.

ICD-10 Classifications

Skeletal muscle relaxants [neuromuscular blocking agents]
Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]
Other neuromuscular dysfunction of bladder
Neuromuscular dysfunction of bladder, unspecified
Neuromuscular scoliosis

Data Source

ClinicalTrials.gov

NCT05718934

Non-Device Trial